In vitro stimulation of plasminogen activator release from vein walls by adrenaline

A KJAELDGAARD, M KJAELDGAARD*

From the Department of Obstetrics and Gynecology, and the *Department of Cardiology, Karolinska Institutet, Huddinge University Hospital, Sweden

SUMMARY The effect of adrenaline on plasminogen activator release was studied in vitro in human vein biopsy specimens, in which the fibrinolytic activity was determined according to the fibrin slide technique. The tissue slides were covered with a thin fibrin film containing 10^{-9} and 10^{-7} M adrenaline and exposed for 30 to 60 minutes. In both concentrations highly significant (p < 0.001) enhancement of fibrinolytic activity was shown, and the enhancement of fibrinolysis was most pronounced during the first 30 minutes of exposure. Stimulation of fibrinolysis was maximal after exposure to the physiological concentration of 10^{-9} M, while no further increase was seen using the pharmacological concentration. These results show that adrenaline has a stimulant effect on tissue fibrinolysis in vitro, and this effect may account for the direct stimulation of fibrinolysis by adrenaline in vivo.

The fibrin slide technique originally described by Todd in 1958 is a widely used histochemical method for showing fibrinolytic activity in tissues.\(^1\) By improving histochemical procedures and criteria for reading slides, this qualitative technique can be used as a semiquantitative method for assessing of plasminogen activator content in various tissues.\(^2\) Using the modification by Pandolfi et al.,\(^3\) it has been shown that impaired fibrinolytic activity in vein walls predisposes to thromboembolic complications.\(^4\)–\(^6\) Furthermore, both stimulation and inhibition of vein wall fibrinolysis after treatment with steroids has been shown.\(^7\)–\(^9\)

In tissues and body fluids two immunologically and structurally different plasminogen activators have been recognised—that is, urokinase and tissue type plasminogen activator. According to immunohistochemical studies, however, the plasminogen activator in the vein wall has been characterised as a tissue type plasminogen activator, while no activity of urokinase could be shown.\(^10\)–\(^11\) Tissue type plasminogen activator is also released into the blood stream after infusion of desamino-8-D-arginine vasopressin (DDAVP) and on stimulation with vasoactive drugs.\(^12\)–\(^15\)

In perfusion studies of isolated organs such as rat hind leg and pig ear, vasoactive drugs such as bradykinin, acetylcholine, and adrenaline enhance plasma fibrinolysis by direct stimulation of vascular plasminogen activator release.\(^13\)–\(^17\) The aim of this investigation was to study the in vitro effect of adrenaline on vein wall fibrinolysis by adding it to the fibrin film covering the tissue slices.

Material and methods

The present series included 20 healthy regularly menstruating women aged 34–51 years (median age 41 years) who were admitted to Huddinge University Hospital for determination of fibrinolytic activity in vein walls. After their informed consent data on age, menstrual cycle, smoking habits, and use of oral contraceptives (including duration and type) were registered before the sampling took place. Four women were cigarette smokers (< 10 cigarettes daily) and six were using combined oral contraceptives. The remaining 10 non-smokers who had never used oral contraceptives served as controls.

In each woman a superficial vein on the dorsal foot was prepared by gentle dissection under local anaesthesia of the surrounding connective tissue containing 2 ml 0.5% prilocain (Citanest, Astra). The vessel specimens, about 0.5 cm in length, were immediately frozen in liquid nitrogen and stored (−20°C) until analysed for fibrinolytic activity.

Accepted for publication 14 May 1986
DETERMINATION OF THE PLASMINOGEN ACTIVATOR ACTIVITY

Fibrinolytic activity in the vein walls was assayed according to the semiquantitative technique previously described by Pandolfi. Briefly, five thin (8 μm) cross sections of the vessel specimens were placed on a glass slide and covered with a thin plasminogen rich fibrin film with and without adrenaline. The fibrin film was obtained by mixing 0.06 ml human fibrinogen (1%, KabiVitrum) and 0.01 ml thrombin (Topostasin Roche, 20 National Institute of Health U/ml saline). After stabilisation at room temperature (21°C) for half an hour the fibrin slides were incubated in a moist chamber (37°C) for 0, 10, 20, and 30 minutes, and fixed in formalin. The slides were then stained with Giemsa solution and Harris's haematoxylin. Fibrinolytic activity was evident by zones of clearing in the fibrin film and estimated blindly by the same laboratory assistant according to a four graded scale (0 = no lysis; 1 = microscopic punctate areas of lysis; 2 = gross lytic areas; 3 = dissolution of most or all fibrin). The fibrinolytic activity in the vein walls was expressed in arbitrary units by summarising the scores of the four different incubation periods, the maximum score thus being 12 arbitrary units.

EXPOSURE TO ADRENALINE

Adrenaline (1 mg/ml, Astra) was diluted 1/2400 and 1/240 000 in saline, and 0.1 ml of these freshly prepared stock solutions was added to 2 ml fibrinogen. Thus the final concentration of adrenaline was 10^{-9} and 10^{-7} M, respectively, in the fibrin film covering the exposed cryostate sections.

STATISTICS

Non-parametric tests—that is, the Kruskal-Wallis one way analysis of variance and the sign test—were used for the statistical evaluation of the results.

Results

Table I shows the mean fibrinolytic activity in human foot veins with and without exposure to adrenaline. In preparations with physiological concentrations of adrenaline (1 nmol/l) a highly significant (p < 0.001) increase in fibrinolytic activity was recorded. After addition of the pharmacological dose (100 nmol/l) the increase was still highly significant (p < 0.001), but no further stimulation of vein fibrinolysis was seen. Smokers and users of oral contraceptives did not differ from controls with respect to vein wall activity and fibrinolytic response to adrenaline.

Table 2 shows the data on the relation between incubation period and stimulating effect of adrenaline on vein wall fibrinolysis. During preincubation for 30 minutes at 21°C, a highly significant increase in fibrinolytic activity was seen in preparations exposed to the physiological concentration, and a significant increase was also seen in the pharmacological concentration. During subsequent incubation at 37°C for 10, 20, and 30 minutes, a further small but consistent increase of about 0.30 arbitrary units was recorded, irrespective of the adrenaline concentration used. Thus the increase in fibrinolytic activity recorded in vein biopsy specimens exposed to adrenaline mainly reflects the stimulating effect during the preincubation period.

The fibrin slides illustrate the typical findings in the present series (fig 1). In this woman no activity was seen in the control preparation, while distinct lytic areas were clearly visible after incubation at 21°C with exposure to adrenaline. After incubation at 37°C, however, no significant difference between the exposed and unexposed vein biopsy specimens could be seen.

Table 1 Fibrinolytic activity in vein biopsy specimens after in vitro exposure to adrenaline

<table>
<thead>
<tr>
<th>Concentration of adrenaline (nmol/l)</th>
<th>fibrin film</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
</tr>
<tr>
<td>No</td>
<td>20</td>
</tr>
<tr>
<td>Mean</td>
<td>4.8</td>
</tr>
<tr>
<td>SD</td>
<td>0.6</td>
</tr>
<tr>
<td>Analysis of variance</td>
<td>p &lt; 0.001</td>
</tr>
</tbody>
</table>

Table 2 Increase of vein wall fibrinolysis after in vitro exposure to adrenaline during preincubation (30 minutes) and subsequent incubation at 37°C

<table>
<thead>
<tr>
<th>Adrenaline concentration</th>
<th>Increase in fibrinolytic activity (arbitrary units)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>After preincubation</td>
<td>During incubation</td>
<td>Total</td>
</tr>
<tr>
<td></td>
<td>Mean</td>
<td>Mean</td>
<td>Mean</td>
</tr>
<tr>
<td>10^{-9} M</td>
<td>0.70*</td>
<td>0.30</td>
<td>1.00*</td>
</tr>
<tr>
<td>10^{-7} M</td>
<td>0.40†</td>
<td>0.35</td>
<td>0.75*</td>
</tr>
</tbody>
</table>

*p < 0.001; †p < 0.05.
Stimulation of plasminogen activator release

Discussion

The present study shows that the fibrinolytic activity in vein walls can be stimulated in vitro by adrenaline added to the fibrin film covering the tissue slices. This enhancing effect on fibrinolysis was already demonstrable in the concentration of $10^{-9}$ M, at which plasma concentration of adrenaline stimulates both β adrenergic (vasodilatation) and α adrenergic (vasoconstriction) receptors in man. Thus vein biopsies for clinical use should be taken during resting conditions in a relaxed patient, as the fibrinolytic activity in patients with vasoconstriction may be increased due to circulating adrenaline. The fibrinolytic response was maximal after exposure to the physiological concentration ($10^{-9}$ M), although similar stimulation of the fibrinolytic activity was found using the pharmacological concentration of $10^{-7}$ M. This concentration is about 200 times lower than that commonly used in local anaesthetic preparations (4–5 μg adrenaline/ml). Accordingly, preparations containing adrenaline or other vasoconstrictive drugs should be avoided if sampling for fibrinolytic studies, considering the strongly stimulating effect of adrenaline on veins exposed to considerably lower adrenaline concentrations.

In the vein biopsy specimens exposed to adrenaline fibrinolysis was clearly stimulated during preincubation, while no significant effect was shown after incubation at 37°C. This may be explained by the fact that, normally, little or no fibrinolytic activity in dorsal foot veins is present after the preincubation period of 30 minutes at room temperature, whereas several distinct lytic areas already appear after the shortest incubation period (10 minutes). Thus the stimulating effect of adrenaline was more easily recognised in preparations with little or no activity than in those with more pronounced activity. This suggests that the release of plasminogen activators induced by adrenaline is relatively small compared with the release dependent on temperature during incubation. Therefore the usefulness of adrenaline as an agent to determine in vitro fibrinolytic release capacity may be limited compared with other substances known to have a high in vivo effect, such as DDAVP.

Our findings of initial stimulation of fibrinolysis in veins exposed in vitro indicate that adrenaline enhances fibrinolysis by direct stimulation of plasminogen activator release from endothelial cells. In man, however, administration of β adrenergic antagonists only partially inhibits the adrenaline induced enhancement of fibrinolysis. Furthermore, the fibrinolytic response to catecholamines and physiological stress such as exercise and smoking may vary...
considerably from subject to subject, as may the response to stasis, acidosis, contact with fibrin, and administration of DDAVP.\textsuperscript{22} This suggests that release of vascular plasminogen activator may be triggered by different but still incompletely known mechanisms.\textsuperscript{14} \textsuperscript{15} Probably the outlined technically simple method used in vitro exposure may also be applied to other fibrinolytically active agents to screen for a possible direct stimulating effect.

References

22 Marsh NA. \textit{Fibrinolysis}. Chichester: John Wiley and Sons, 1981.

Requests for reprints to: Dr A Kjaeldgaard, Department of Obstetrics and Gynaecology, Karolinska Institutet, Huddinge University Hospital, S-141 86 Huddinge, Sweden.
In vitro stimulation of plasminogen activator release from vein walls by adrenaline.
A Kjaeldgaard and M Kjaeldgaard

doi: 10.1136/jcp.39.11.1241

Updated information and services can be found at:
[http://jcp.bmj.com/content/39/11/1241](http://jcp.bmj.com/content/39/11/1241)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)